We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is seeking comments on a proposed 1,183-day patent extension — roughly three years — for Medtronic’s Talent abdominal stent graft system due to the length of the regulatory review period.